Lumosa Therapeutics Co (ROCO:6535) Beta: 0.6736 (As of Jun. 26, 2026)


ROCO:6535 Lumosa Therapeutics Co Ltd ROCO:6535
72 GF Score
Price NT$97.00
GF Value NT$130.67
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lumosa Therapeutics Co Beta?

Lumosa Therapeutics Co ROCO:6535 -2.81% 72 Beta is 0.6736 as of Jun. 26, 2026. GuruFocus rates ROCO:6535 with a GF Score™ of 72/100 and a GF Value™ of NT$130.67 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Lumosa Therapeutics Co's Beta is 0.6736.


Lumosa Therapeutics Co  (ROCO:6535) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Lumosa Therapeutics Co Beta Related Terms


Lumosa Therapeutics Co Beta Historical Data

* Premium members only.

The historical data trend for Lumosa Therapeutics Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumosa Therapeutics Co Beta Chart

Lumosa Therapeutics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 0.72 0.74 0.73 0.00

Lumosa Therapeutics Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 0.00 0.00 0.00 0.00

ROCO:6535 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Lumosa Therapeutics Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumosa Therapeutics Co Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's Beta distribution charts can be found below:

* The bar in red indicates where Lumosa Therapeutics Co's Beta falls into.


ROCO:6535
72GF Score
Lumosa Therapeutics Co Ltd ROCO:6535
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumosa Therapeutics Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.6736 mean?
Lumosa Therapeutics Co (ROCO:6535) has a Beta of 0.6736 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Lumosa Therapeutics Co and its competitors.
Is Lumosa Therapeutics Co's Beta too high?
Lumosa Therapeutics Co's current Beta is 0.6736. Overall, Lumosa Therapeutics Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's Beta compare to VRTX and REGN?
Lumosa Therapeutics Co's Beta of 0.6736 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Lumosa Therapeutics Co and its competitors. Lumosa Therapeutics Co's current Beta is 0.6736. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$130.67, compared to a current price of NT$97.00 — trading 25.8% below its estimated fair value. The current Beta is 0.6736. Lumosa Therapeutics Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current Beta is 0.6736 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?

Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued. The current stock price of NT$97.00 is trading 25.8% below its estimated GF Value™ of NT$130.67. GuruFocus considers Lumosa Therapeutics Co to be Modestly Undervalued.

Key valuation signals for ROCO:6535:

  • Beta: 0.6736
  • GF Value™: NT$130.67 vs. price of NT$97.00 (25.8% below fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lumosa Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
72GF Score

Get the complete analysis for ROCO:6535

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$97.00
Price
NT$130.67
GF Value